Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Chest|November 7, 2009
Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung studyJonathan Goldin, Robert Elashoff, Hyun J Kim, et al.
ACR Open Rheumatology|December 5, 2020
Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and IIElizabeth R Volkmann, Virginia Steen, Ning Li, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 21, 2019
Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung DiseaseGrace Hyun J Kim, Donald P Tashkin, Pechin Lo, et al.
Arthritis Care & Research|March 14, 2022
Blood Neutrophil Count and Neutrophil-to-Lymphocyte Ratio for Prediction of Disease Progression and Mortality in Two Independent Systemic Sclerosis CohortsNancy Wareing, Vishnu Mohan, Rana Taherian, et al.
The Journal of Rheumatology|February 17, 2019
Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and IIElizabeth R Volkmann, Donald P Tashkin, Myung Sim, et al.
American Journal of Respiratory and Critical Care Medicine|September 29, 2007
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung diseaseCharlie Strange, Marcy B Bolster, Michael D Roth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironmentLinda M Liau, Robert M Prins, Sylvia M Kiertscher, et al.
Seminars in Arthritis and Rheumatism|September 9, 2020
The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosisElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.
Chest|December 26, 2016
Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study IIDonald P Tashkin, Elizabeth R Volkmann, Chi-Hong Tseng, et al.
Annals of the Rheumatic Diseases|January 14, 2016
Transitions to different patterns of interstitial lung disease in scleroderma with and without treatmentHyun J Kim, Donald P Tashkin, David W Gjertson, et al.
Pageof 10